Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Use of infliximab in pediatric patients with inflammatory bowel disease
Autore:
Serrano, MS; Schmidt-Sommerfeld, E; Kilbaugh, TJ; Brown, RF; Udall, JN; Mannick, EE;
Indirizzi:
Louisiana State Univ, Med Ctr, Dept Pediat, Div Gastroenterol & Nutr, New Orleans, LA 70112 USA Louisiana State Univ New Orleans LA USA 70112 , New Orleans, LA 70112 USA New Orleans Childrens Hosp, New Orleans, LA 70112 USA New Orleans Childrens Hosp New Orleans LA USA 70112 Orleans, LA 70112 USA
Titolo Testata:
ANNALS OF PHARMACOTHERAPY
fascicolo: 7-8, volume: 35, anno: 2001,
pagine: 823 - 828
SICI:
1060-0280(200107/08)35:7-8<823:UOIIPP>2.0.ZU;2-B
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; CHIMERIC MONOCLONAL-ANTIBODY; CROHNS-DISEASE; FACTOR-ALPHA; ULCERATIVE-COLITIS; CA2; POLYMORPHISMS; INHIBITION; INFECTION; MARKERS;
Keywords:
anti-tumor necrosis factory alpha; Crohn's disease; infliximab; ulcerative colitis;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
22
Recensione:
Indirizzi per estratti:
Indirizzo: Serrano, MS Louisiana State Univ, Med Ctr, Dept Pediat, Div Gastroenterol & Nutr, 1542Tulane Ave, New Orleans, LA 70112 USA Louisiana State Univ 1542Tulane Ave New Orleans LA USA 70112
Citazione:
M.S. Serrano et al., "Use of infliximab in pediatric patients with inflammatory bowel disease", ANN PHARMAC, 35(7-8), 2001, pp. 823-828

Abstract

BACKGROUND: The concentration of tumor necrosis factor, a proinflammatory cytokine, is increased in the gastrointestinal mucosa of patients with active Crohn's disease (CID) and ulcerative colitis (UC). Neutralization of tumor necrosis factor decreases the mucosal inflammatory response of adults with CD. Little information is available on the use of monoclonal antibody totumor necrosis factor (infliximab) in children and adolescents with CD or UC. OBJECTIVE: To evaluate the clinical response and side effects of patients to infliximab. METHODS: A retrospective review of data regarding 18 pediatric and adolescent patients with active CID (n = 15) and UC (n = 3) poorly controlled withconventional therapy. All patients received one to six intravenous infusions of infliximab 5 mg/kg, while receiving their usual medications. RESULTS: All patients experienced clinical improvement, including decreasein the frequency of stooling and resolution of extraintestinal symptoms such as arthropathy, malaise, and skin manifestations after treatment with infliximab. All but one patient had a documented decrease in the erythrocyte sedimentation rate. Prednisone dosage was tapered in all but two patients, and discontinued in seven patients. Intravenous infusion of infliximab was well tolerated. One patient developed a rash several days after the infusion. A patient who received six infliximab infusions developed recurrent Staphylococcus aureus infections, as well as septic arthritis and chronic osteomyelitis during the follow-up period, raising the issue of the long-term safety of infliximab. CONCLUSIONS: Treatment of our patients with refractory CID and UC with infliximab was associated with remarkable clinical improvement. Although the drug may have an important role in their management, further assessment of long-term safety and efficacy is needed.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 17:47:43